Responses to Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation

Toulouse University Hospital

Status: Completed

Conditions: Lung Cancer

Treatments: Other: No specific intervention

Study type: Observational

Funder types: Other

Identifiers

NCT02827357

14 7305 03

Details and patient eligibility

About

This chart review describe the response to systemic chemotherapy of patients with non-small cell lung cancer (NSCLC) harbouring a known somatic activating human epidermal growth factor receptor 2 (HER2) mutation. The analysis of this data will provide an initial description of the response to systemic chemotherapy in patients with NSCLC harboring an activating HER2 mutation in order to inform the design and powering of future randomized controlled clinical trials of HER2-directed therapy.

Enrollment: 101 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with advanced nonsmall-cell lung cancer
• known HER2 exon-20 insertion
• treated with chemotherapy and/or HER2-targeted drugs

Exclusion criteria

• none